Gisele Nishiguchi
St. Jude Children's Research Hospital(US)
Publications by Year
Research Areas
Cancer Mechanisms and Therapy, Melanoma and MAPK Pathways, Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Ubiquitin and proteasome pathways
Most-Cited Works
- → Pyrazole Ligands: Structure−Affinity/Activity Relationships and Estrogen Receptor-α-Selective Agonists(2000)759 cited
- → Phenyl‐Glutarimides: Alternative Cereblon Binders for the Design of PROTACs(2021)145 cited
- → Dual Allosteric Inhibition of SHP2 Phosphatase(2018)127 cited
- → Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers(2014)111 cited
- → Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators(2021)97 cited
- → Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies(2015)74 cited
- → Discovery of novel 3,5-disubstituted indole derivatives as potent inhibitors of Pim-1, Pim-2, and Pim-3 protein kinases(2011)62 cited
- → Phenyl Dihydrouracil: An Alternative Cereblon Binder for PROTAC Design(2023)59 cited
- → Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors(2013)53 cited
- → Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers(2017)44 cited